Engineering TIL to Address the Obstacles to Wider Patient Eligibility
- Optimizing manufacturing to enable tumor tissue procurement by core needle biopsy and improve TIL functionality
- Applying membrane-bound IL15 expression to enable a low-dose lymphodepletion regimen
- Removing IL2-related toxicities using localized, regulatable, membrane-bound cytokine delivery
- Evaluating early safety and efficacy signals from engineered TIL in melanoma